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INTRODUCTION
Elastin is involved in the maintenance of vascular compli-
ance. A change in the balance between elastin synthesis and 
degradation may lead to the development of a pathological 
vascular condition.1 Elastin degradation has been reported to 
be a determinant of arterial stiffness and has prognostic value 
for clinical outcomes in high-risk populations.2 In many stud-
ies, elastin degradation peptides have been proposed as par-
ticipating in the progression of atherosclerosis through the ac-
tivation of various biological processes.3
For decades, anti-elastin antibodies have been assayed by 
immunological techniques. Levels of the antibody and the 
changes that occur in normal and pathological conditions 
have also been investigated in prior studies.4-6 Therein, blood 
levels of elastin peptides and those of the antibodies against 
elastin peptides did not correlate.7,8 Moreover, elastin degra-
dation by diverse enzymes can release various epitopes, and 
any antibody-disease association may depend on the origin of 
the epitopes.9 To date, the clinical relevance of antibody levels 
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is not thoroughly understood and interpretation of antibody 
levels warrants caution. Although a few studies have investi-
gated anti-elastin antibody levels in atherosclerotic cardiovas-
cular disease, across these studies, the relationship between 
antibody levels and atherosclerosis has been inconsistent.5,6,10
The aim of this study was to evaluate the association be-
tween anti-elastin antibody levels and coronary artery disease 
(CAD). We also assessed relationships between antibody lev-
els and cardiovascular risk factors using a newly developed 
enzyme-linked immunosorbent assay (ELISA). We found that 
lower levels of anti-elastin are related to CAD and that this re-
lation is linked to arterial stiffness. 
MATERIALS AND METHODS
Study patients 
This study included 171 patients with CAD and 174 control 
subjects without CAD. Participants were drawn from the data-
base of the Cardiovascular Genome Center at Yonsei Universi-
ty Health System, Seoul, Korea. CAD patients were recruited 
when undergoing coronary angiography for chest discomfort 
or chest pain. Subjects aged 30–70 years with stenosis >50% in 
at least one epicardial coronary artery were included. The ex-
clusion criteria included uncontrolled high blood pressure (BP) 
(systolic BP >180 mm Hg or diastolic BP 110 mm Hg); uncon-
trolled diabetes mellitus (fasting blood glucose 180 mg/dL); a 
history of structural heart disease with or without heart fail-
ure; thyroid [thyroid stimulating hormone <lower limit of nor-
mal or upper limit of normal (ULN)], liver (serum amino-
transferase >2×ULN) or kidney disease (serum creatinine >1.5 
mg/dL); acute or chronic inflammatory disease; and malig-
nant neoplasm. Control subjects were matched for sex and 
age (±5 years), and selected from the database of a communi-
ty health check-up center in Mapo-gu, Seoul, Korea. Written 
informed consent was obtained from all participants, and the 
study protocol was approved by the Institutional Review Board 
of Severance Hospital, Seoul, Korea.
Collection of clinical and angiographic data
At the time of enrollment, subjects were interviewed regard-
ing their individual medical histories and underwent com-
plete physical examinations. Hypertension was defined as a 
BP >140/90 mm Hg on two or more occasions or undergoing 
antihypertensive treatment. Diabetes mellitus was defined as 
a fasting blood glucose ≥126 mg/dL, postprandial blood glu-
cose ≥200 mg/dL, or current treatment with hypoglycemic 
medications. Hyperlipidemia was defined as low-density li-
poprotein-cholesterol ≥160 mg/dL. CAD characteristics were 
evaluated by a cardiologist who was blinded to the study’s 
purpose. The cardiologist first evaluated the most severe clini-
cal presentation of CAD in the patient’s history, and then the 
number of coronary arteries with at least one stenosis of >50%. 
After a 12-h fasting period, venous blood samples were col-
lected, centrifuged, and stored at -80°C.
Measurement of augmentation index and pulse wave 
velocity
The augmentation index (AI) was measured in the sitting po-
sition after a 5-min rest using a radial artery tonometry device 
(SphygmoCor, AtCor Medical, Sydney, Australia), as described 
previously.11 The central BP was calibrated to the brachial BP 
measured using the OMRON HEM 7080IT (Omron Health-
care, Kyoto, Japan). Briefly, using a high-fidelity micromanom-
eter (Millar Instruments, Houston, TX, USA), peripheral pres-
sure waveforms from the radial artery were recorded at the 
wrist of the dominant arm. Central systolic BP, diastolic BP, 
pulse pressure, augmentation pressure, and AI were acquired 
from the pulse waveform analysis. Augmentation pressure is 
the difference between the second and first systolic peak pres-
sures, and the AI is defined as the ratio of augmentation pres-
sure to aortic pulse pressure. 
The heart-to-femoral pulse wave velocity (hfPWV) was de-
termined by a VP-2000 pulse wave unit (Nippon Co. Ltd., Ko-
maki, Japan), as described previously.12 Briefly, after an over-
night fast and a 5-min rest, the PWV was measured in a supine 
position. Carotid and femoral artery pressure waveforms were 
recorded from multi-element tonometry sensors at the left 
common carotid and left femoral arteries. The electrocardio-
gram was monitored from electrodes placed on both wrists. 
Heart sounds were detected by a microphone placed on the left 
sternal edge in the third intercostal space. The hfPWV, a mark-
er of central aortic stiffness, was calculated using the equation 
Lhf/(Thc+Tcf). Lhf refers to the distance from the heart to the 
femoral artery, Thc is the interval between S2 and the notch of 
the carotid pulse wave, and Tcf is the time interval between the 
carotid and femoral artery pulse wave. 
Enzyme-linked immunosorbent assay (ELISA) for an-
ti-elastin antibody titer
The anti-human elastin antibody quantification assay was per-
formed using a modified ELISA protocol.13 Briefly, human 
aortic elastin peptides were purchased from EPC (Owensville, 
MO, USA) and dissolved and used to coat ELISA plates 
(Greiner, Kremsmunster, Austria). After incubation and wash-
ing with phosphate-buffered saline (PBS) containing Tween 
20 (BioRad, Bedford, MA, USA) (PBS/Tween), plates were 
blocked by I-block (Tropix, Bedford, MA, USA) and incubat-
ed. After washing with PBS/Tween, human serum samples 
were diluted and incubated. After washing, biotinylated 
chicken anti-human IgG antibody (Immunology Consultants 
Laboratory, Newberg, OR, USA) was added and the samples 
were incubated. Plates were washed again, then alkaline 
phosphatase-conjugated streptavidin (BD bioscience, San Di-
ego, CA, USA) was added, and the samples were incubated. 
After a final wash, alkaline phosphatase substrate (Sigma, St. 
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Louis, MO, USA) was added and the plates were allowed to 
develop until the standard curve was readily apparent. The 
colorimetric reaction was terminated by adding sodium hy-
droxide, and the optical density of the individual wells was 
determined. We selected one sample from a subject with em-
physema that showed a very high optical density as a stan-
dard for relative quantification in all assays. 
Statistical analysis
Differences between cases and controls were evaluated using 
chi-square tests for categorical variables and Student’s t-tests 
for continuous variables. As anti-elastin levels had a log-nor-
mal distribution, they were log-transformed before analysis. 
The relationship between anti-elastin titers and clinical or 
vascular characteristics was analyzed by Student’s t-test or an 
analysis of variance test. To identify independent associations 
between anti-elastin levels and vascular characteristics, uni-
variate and multivariate linear regression analyses were per-
formed. Variables that showed p<0.15 in the univariate analy-
sis were entered into the multivariate analysis. SPSS software, 
version 18 (SPSS Inc., Chicago, IL, USA) was used for all statis-
tical analyses.
RESULTS
Characteristics of the study subjects
The characteristics of the 345 study subjects (mean age: 51.0 
±7.7 years, men: 63%) are presented in Table 1. Hypertension, 
diabetes mellitus, and hyperlipidemia were observed with 
greater frequency in the CAD group than in the control group. 
CAD patients also had a higher diastolic BP, AI, and hfPWV. The 
blood anti-elastin antibodies levels were significantly lower in 
the CAD group than in the control group (p<0.001). In the CAD 
group, 39% of subjects experienced myocardial infarction and 
41% of coronary angiographies revealed multi-vessel involve-
ment. 
Determinants of anti-elastin
The log anti-elastin levels were significantly lower in CAD pa-
tients, men, and individuals with hypertension, diabetes mel-
litus, hyperlipidemia, or high hfPWV (Figs. 1 and 2). In CAD 
patients, anti-elastin levels were not dependent on myocardi-
al infarction history or the number of diseased vessels (Fig. 2). 
In univariate analysis, male sex, hypertension, diabetes melli-
tus, hyperlipidemia, and hfPWV were inversely correlated with 
log anti-elastin levels. In multivariate analysis, male sex, dia-
betes mellitus, hyperlipidemia, and AI were identified as de-
terminants of log anti-elastin levels (Figs. 1 and 2, Table 2). In 
the analysis of potential AI determinants, the relationship be-
tween index and log anti-elastin levels was again found to be 
significant and independent of other clinical risk factors (Sup-
plementary Table 1, only online). 
DISCUSSION
The present study assessed the relationship between anti-
elastin antibody levels and CAD and its characteristics. This 
study revealed that anti-elastin levels are lower in CAD pa-
tients than in matched controls. Anti-elastin levels were asso-
ciated with sex, hypertension, diabetes mellitus, hyperlipid-
emia, and arterial stiffness, but not with myocardial infarction 
history or angiographic severity of CAD. AI, a parameter of ar-
Table 1. Baseline Characteristics of All Study Subjects
All subjects
(n=345)
Control
(n=174)
CAD
(n=171)
p value
Age, yrs 51.0±7.7 50.9±7.7 51.2±7.7 0.75
Males 219 (63) 111 (64) 108 (63) 0.91
Medical history
Hypertension 147 (43) 55 (32) 92 (53) <0.001
Diabetes mellitus 60 (17) 10 (6) 50 (29) <0.001
Hyperlipidemia 122 (35) 41 (24) 81 (47) <0.001
Current smoker 78 (23) 38 (22) 39 (23) 0.90
Physical findings
Body mass index, kg/m2 25.2±3.2 25.0±3.3 25.4±3.0 0.23
Systolic BP, mm Hg 123±18 121±15 125±20 0.07
Diastolic BP, mm Hg 77±12 76±13 79±11 0.02
Arterial stiffness
Augmentation index 15.2±18.9 12.1±19.4 18.2±17.8 0.003
hfPWV, cm/sec 899±157 874±158 923±153 0.003
CAD characteristics
Clinical diagnosis
Angina pectoris 107 (61)
Myocardial infarction 67 (39)
Number of diseased vessels
1 102 (59)
2 40 (23)
3 32 (18)
Anti-elastin, a.u.
113 
(59, 211)
197 
(147, 270)
63 
(40, 96)
<0.001
Log anti-elastin 4.70±0.86 5.24±0.60 4.17±0.73 <0.001
Medications
ACE inhibitors or ARBs 139 (40) 31 (18) 108 (63) <0.001
Calcium channel blockers 103 (30) 28 (16) 75 (44) <0.001
Beta blockers 117 (34) 15 (9) 102 (60) <0.001
Diuretics 54 (16) 18 (10) 36 (21) 0.01
Statins 152 (44) 21 (12) 131 (77) <0.001
Biguanides 30 (9) 8 (5) 22 (13) 0.01
Sulfonylurea 20 (6) 4 (2) 16 (9) 0.01
BP, blood pressure; CAD, coronary artery disease; a.u., arbitrary unit; ACE, 
angiotensin converting enzyme; ARB, angiotensin receptor blocker; hfPWV, 
heart-to-femoral pulse wave velocity.
Values are presented as the mean±SD, n (%), or median (interquartile range).
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terial stiffness, was identified as a determinant of antibody lev-
els independent of other confounding risk factors. Our results 
suggest that lower anti-elastin levels are related to CAD and 
that this relation is linked to arterial stiffness rather than ad-
vancement of atherosclerosis. We quantified this antibody us-
ing a novel assay against aortic elastin peptides, and our result 
may be used as basic data for further validation studies. 
One major finding of our study was lower anti-elastin anti-
body levels in CAD patients than in controls. This result is 
consistent with that reported by Baydanoff, et al.,6 which indi-
cated that anti-human aortic elastin antibody levels were low-
er in patients with atherosclerosis. Although its mechanism 
was not fully elucidated at that time, the authors suggested an 
adaptive restriction of the immune response to avoid aggrava-
tion of the atherosclerosis as a possible cause. However, the 
antibody levels and elastin-derived peptide levels did not cor-
relate. In the same patients with atherosclerosis, their elastin 
degradation peptide levels were higher than those in other 
subjects.8 In another study,7 the antibody and peptide levels 
did not correlate either. Clarification of the relationship be-
tween antibody levels and elastin-derived peptide concentra-
tions may help better understand their physiology. Mean-
while, a few studies have shown results that differ from ours. 
In one study, anti-elastin peptide antibody levels were higher 
in patients with ischemic heart disease and obliterative arte-
riosclerosis of the legs.5 In another, a significant increase in se-
rum alpha-anti-elastin antibody levels was demonstrated in 
patients with carotid plaque destabilization.10 It was also re-
ported that cathepsins K and S at vascular matrix remodeling 
can degrade elastin, and this supports that elastolytic prod-
ucts can be elevated in progressed atherosclerosis.14 Further-
more, studies have shown that atherosclerosis-associated cyto-
kines augment cysteinyl cathepsin activity, which can promote 
elastin degradation, in various vascular diseases.15 Taken to-
gether, caution should be exercised when interpreting anti-
elastin antibody levels in clinical situations. 
As mentioned above, the mechanisms and implications of 
varying anti-elastin antibody levels have not been fully under-
stood. However, several possible roles have been proposed. 
Anti-elastin antibody binds elastin peptides and may block 
their chemotactic effect on inflammatory cells.16 Thus, lower 
antibody levels may be insufficient to block this effect of elas-
tin peptides. Secondly, hyperactivity of the immune response 
to elastin may cause more vascular damage. Therefore, a de-
crease in antibody levels may result from the impaired im-
mune reaction against elastin to reduce the aggravation of 
atherosclerosis.6 Nevertheless, uncovering the significance of 
the lower antibody levels in our study requires further analy-
sis. For instance, in the current study, antibody levels were in-
dependently associated with sex, diabetes mellitus, hyperlip-
Fig. 1. Associations between anti-elastin levels and clinical characteristics. Levels of log anti-elastin were lower in CAD patients than in control sub-
jects (A). Anti-elastin levels were also significantly lower in males (B) and subjects with hypertension (C), DM (D), or hyperlipidemia (E), compared to 
each subgroup’s respective counterpart. CAD, coronary artery disease; DM, diabetes mellitus.
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idemia, and an arterial stiffness index. Although antibody 
level was significantly associated with CAD, other cardiovas-
cular risk factors also showed correlations with antibody lev-
els. Thus, it is assumed that the relationship between antibody 
levels and CAD can be influenced in part by the vascular con-
ditions developed by other risk factors. We found arterial stiff-
ness to be an independent determinant of anti-elastin. Risk 
factors can coexist in a single patient and influence one anoth-
er. Therefore, caution should be taken in interpreting the level 
of an antibody that is interrelated to other factors. Another 
point to consider is whether the antibody levels reflect a gen-
eral vascular pathology or CAD specifically. Although the an-
tibody levels were correlated with the presence of CAD in our 
study, they were not associated with disease advancement. 
The antibody concentration was linked to the arterial stiffness 
index, and this concentration may indicate functional change 
of non-coronary vasculature as well as the risk of CAD. 
The relationship between elastin degradation and arterial 
stiffness has been investigated in many studies. Ruseva, et al.17 
showed that the anti-elastin antibody level is lower when elas-
tin degradation is experimentally slowed in rats. Maclay, et al.4 
measured cutaneous elastin degradation and reported that 
Fig. 2. Associations between anti-elastin levels and arterial stiffness or the severity of atherosclerotic CAD. Though the levels of log anti-elastin did 
not differ significantly among the five groups stratified according to augmentation index values (A), they were lower in subjects with higher hfPWV 
(B). Log anti-elastin levels were similar in the angina pectoris and myocardial infarction subgroups (C). Anti-elastin levels were also similar among 
subgroups with different numbers of diseased vessels (D). Subgroups classified by augmentation index or hfPWV were analyzed in total subjects 
(n=345), while those by clinical or angiographic severity of CAD were analyzed in CAD patients (n=171). CAD, coronary artery disease; hfPWV, heart-to-
femoral pulse wave velocity.
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this was positively associated with PWV. Our results are not in 
agreement with these reports, and therefore, clarification of 
the association between antibody level and stiffness is need-
ed. Notably, whether the blood antibody level correlates with 
arterial stiffness, whether changes in antibody levels have 
clinically significant implications, and which clinical factors 
may influence antibody levels remain to be clarified. In this re-
gard, our analysis of the association between antibody levels 
and clinical risk factors might serve as helpful basic data. 
A prior study demonstrated that female mice have higher 
anti-elastin antibody levels than males, which is consistent 
with our data.18 The authors suggested that reproductive organ 
remodeling in female mice may be the cause of this finding, 
although this does not sound plausible in our subjects. Previ-
ous studies on the association between diabetes mellitus and 
antibody levels did not show consistent results. The fibulin-1 
level, an elastin-associated protein, was lower in patients with 
type 2 diabetes than in controls.19 Conversely, in another study 
conducted in diabetic children, anti-elastin IgG level was pos-
itively correlated with diabetes duration, hemoglobin A1c lev-
el, and the level of antibodies to advanced glycation end-prod-
ucts. Although low-density lipoproteins interact with arterial 
elastin during the development of atherosclerosis,20 the data 
on the blood levels of elastin peptide or the antibody against it 
in hypercholesterolemia are limited. Interestingly, Fülöp, et 
al.5 showed that anti-elastin antibody levels decreased in sub-
jects with IV hyperlipoproteinemia with hypertriglyceridemia, 
whereas we found that antibody levels were lower in patients 
with a history of hypercholesterolemia. On the other hand, it 
was shown in the study of Baydanoff, et al.8 that anti-elastin an-
tibody levels decrease after the age of 60 years. In their study, 
no significant change in antibody levels was noticed until that 
age. In our study, antibody levels did not vary with subjects’ 
age. However, because the age range in our subjects was rela-
tively narrow, it is difficult to say whether age is significantly 
associated with antibody levels. 
Our study was designed with well-matched cases and con-
trol subjects, and systemically assessed the effects of CAD or 
individual cardiovascular risk factors on anti-elastin antibody 
levels. In particular, the analysis of associations with detailed 
vascular characteristics is the strength of this study. Several 
findings were demonstrated for the first time in the current 
study, although they require further validation. Some limita-
tions of our study can be pointed out. The contribution of AI to 
anti-elastin levels was significant but weak (beta=-0.006) and 
its clinical impact could be modest. In our study, we could only 
measure anti-elastin antibody levels. A simultaneous exami-
nation of elastin peptide level may have given us more insight 
into the pathological role and clinical interpretation of antibody 
levels. In addition, patients with CAD had slightly but signifi-
cantly higher diastolic BP. Although it did not show significant 
relationship with arterial stiffness in our data, it could be one 
of confounders in the analyses. Lastly, we excluded subjects with 
uncontrolled hypertension or diabetes mellitus and these fac-
tors with medications might have partially affected our results.
To summarize, anti-elastin antibody levels were lower in 
Table 2. Determinants of Log Anti-Elastin in All Study Subjects
Total subjects (n=345)
Univariate analysis Multivariate analysis
Beta SE p value Beta SE p value
Age 0.002 0.006 0.75 - - NS
Sex (male) -0.210 0.096 0.03 -0.377 0.105 <0.001
Hypertension -0.324 0.093 0.001 - - NS
Diabetes mellitus -0.626 0.119 <0.001 -0.615 0.117 <0.001
Hyperlipidemia -0.343 0.096 <0.001 -0.285 0.092 0.002
Smoking -0.114 0.112 0.31 - - NS
Systolic BP -0.004 0.003 0.11 - - NS
Body mass index -0.025 0.015 0.09 - - NS
Augmentation index -0.004 0.002 0.12 -0.006 0.003 0.02 
hfPWV -0.001 0.000 0.01 - - NS
Medications
ACE inhibitors or ARBs -0.111 0.100 0.27 - - NS
Calcium channel blockers -0.126 0.097 0.20 - - NS
Beta blockers -0.163 0.104 0.12 - - NS
Diuretics -0.061 0.122 0.62 - - NS
Statins -0.175 0.109 0.11 - - NS
Biguanides -0.099 0.165 0.55 - - NS
Sulfonylurea -0.180 0.197 0.36 - - NS
BP, blood pressure; hfPWV, heart to femoral pulse wave velocity; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; SE, standard error; 
NS, not significant.
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CAD patients and associated with male sex and a history of 
hypertension, diabetes mellitus, or hyperlipidemia. Antibody 
levels negatively correlated with arterial stiffness, but not with 
myocardial infarction history or the severity of CAD. In con-
clusion, a lower anti-elastin antibody titer is related to CAD and 
this relation is linked to arterial stiffness rather than to the ad-
vancement of atherosclerosis. Our results may provide the ba-
sic data for further validation studies of this novel assay.
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